There is a dose-response relationship between current benzodiazepine receptor agonist (BZRA) use and the risk of hospitalization for pneumonia, a recent study suggests. The population-based nested case-control study conducted between 2002 and 2012 included new BZRA users who did not have any BZRA prescriptions in the preceding 2 years and identified 12,002 individuals hospitalized for pneumonia and 12,002 disease risk score-matched control subjects. Researchers found:
- Current BZRA exposure was associated with hospitalization for pneumonia (adjusted OR [aOR], 1.86).
- Benzodiazepine hypnotic agents (aOR, 2.42) had a higher risk of pneumonia than did benzodiazepine anxiolytic agents (aOR, 1.53) or nonbenzodiazepine hypnotic agents (aOR, 1.60).
- Midazolam had a higher risk (aOR, 5.77) of hospitalizations for pneumonia than other individual BZRAs.
Chen T, Winkelman JW, Mao W, et al. The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia. A nationwide population-based nested case-control study. CHEST. 2017;153:161-171. doi:10.1016/j.chest.2017.07.030.
Benzodiazepine use, particularly when used as a sleep aid, has many adverse effects and this study adds another potential adverse effect to the list. Psychotropic and hypnotic drugs can impair cognitive and psychomotor abilities. In fact, a 2013 study suggested an increase in motor vehicle accidents in individuals who were taking benzodiazepines or other sleep enhancing medications such as zolpidem.1 Remember, due to excess daytime sedation, the FDA in 2013 lowered the recommended dose of zolpidem due to excessive daytime sleepiness.2 The current study gives another reason to think twice before prescribing benzodiazepines to aid with sleeping. — Neil Skolnik, MD
- Chang CM, Wu EC, Chen CY, et al. Br J Clin Pharmacol. 2013;75(4):1125-33. doi:10.1111/j.1365-2125.2012.04410.x.
- US Food and Drug Administration. FDA Safety Announcement. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). January 10, 2013. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf. Accessed January 10, 2018.
This Week's Must Reads
ACP Guidance on Pharmacologic Treatment of T2D, Ann Intern Med; ePub 2018 Mar 6; Qaseem, et al
Opioid vs Nonopioid Meds for Pain-Related Function, JAMA; ePub 2018 Mar 6; Krebs, Gravely, et al
Obesity Progression and Incident Diabetes, Diabetes Care; ePub 2018 Mar 5; Stokes, et al
E-Cigarette Use and Progression to Smoking, Pediatrics; ePub 2018 Mar 5; Chaffee, et al
Intensive BP Treatment & Subsequent CVD Risk, J Am Coll Cardiol; ePub 2018 Mar 7; Phillips, et al
Must Reads in Immunology
CVD Risk with LABAs and LAMAs in COPD, JAMA Intern Med; ePub 2018 Jan 2; Wang, et al
Benzodiazepine Use & Risk of Pneumonia, CHEST; 2018 Jan; Chen, Winkelman, et al
Pharmacologic Tx of Seasonal Allergic Rhinitis, Ann Intern Med; ePub 2017 Nov 28; Wallace, et al
FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20
Self-Administered Treatment for Latent Tuberculosis, Ann Intern Med; ePub 2017 Nov 7; Belknap, et al